Monitoring the clinical course of disease

Monitoring patients with idiopathic pulmonary fibrosis (IPF) is important to identify patients with disease progression and/or potential treatment complications.2

Monitoring should be done every four to six months or sooner as clinically indicated.2

In the absence of another identifiable cause, the presence of any of the following indicates progressive disease:2

  • progressive dyspnoea (objectively assessed)
  • progressive, sustained decrease from baseline in absolute forced vital capacity
  • progressive, sustained decrease from baseline in absolute DLCO (corrected for haemoglobin)
  • progression of fibrosis from baseline on high-resolution computed tomography
  • acute exacerbation
  • death from respiratory failure

Pulmonary function testing provides the most standardised approach to monitoring and quantification of disease progression.2

Discover the current interventions for patients with IPF and why early treatment is so important 
Login/ Register Maximise Minimise